Edition:
India

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

2.87USD
19 Mar 2019
Change (% chg)

$-0.02 (-0.69%)
Prev Close
$2.89
Open
$2.93
Day's High
$2.99
Day's Low
$2.72
Volume
179,979
Avg. Vol
142,922
52-wk High
$6.73
52-wk Low
$1.15

Latest Key Developments (Source: Significant Developments)

Conatus Pharmaceuticals Reports Qtrly Loss Per Share $0.13
Saturday, 9 Mar 2019 

March 8 (Reuters) - Conatus Pharmaceuticals Inc ::CONATUS PHARMACEUTICALS REPORTS 2018 FINANCIAL RESULTS AND PROGRAM UPDATES.Q4 REVENUE $7.4 MILLION VERSUS REFINITIV IBES ESTIMATE OF $8.6 MILLION.QTRLY LOSS PER SHARE $0.13.Q4 EARNINGS PER SHARE VIEW $-0.14 -- REFINITIV IBES DATA.ANNOUNCING SELECTION OF ITS FIRST INTERNALLY DEVELOPED PRODUCT CANDIDATE, CTS-2090.CTS-2090 INITIAL CLINICAL TRIAL EXPECTED TO BEGIN BY FIRST HALF OF 2020.  Full Article

Conatus Pharmaceuticals Qtrly Loss Per Share $0.15
Thursday, 2 Aug 2018 

Aug 1 (Reuters) - Conatus Pharmaceuticals Inc ::CONATUS PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROGRAM UPDATES.Q2 REVENUE $8.8 MILLION VERSUS I/B/E/S VIEW $9.1 MILLION.QTRLY LOSS PER SHARE $0.15.  Full Article

Conatus Pharmaceuticals Announces Top-Line Results From Phase 2B POLT-HCV SVR Clinical Trial
Thursday, 5 Apr 2018 

April 4 (Reuters) - Conatus Pharmaceuticals Inc ::CONATUS PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM PHASE 2B POLT-HCV SVR CLINICAL TRIAL.THE TRIAL DID NOT MEET ITS PRIMARY ENDPOINT IN HETEROGENEOUS OVERALL TRIAL POPULATION.BASED PROOF OF CONCEPT IN LIVER FIBROSIS AND CIRRHOSIS SUPPORTS FURTHER EVALUATION.CONATUS PHARMACEUTICALS INC - ENCORE-NF FOR NASH FIBROSIS TOP-LINE RESULTS EXPECTED IN FIRST HALF OF 2019.CONATUS PHARMACEUTICALS INC - ENCORE-LF FOR LIVER FUNCTION WITH TOP-LINE RESULTS EXPECTED IN SECOND HALF OF 2019.  Full Article

Conatus Pharmaceuticals reports Q3 revenue of $9.6 million
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Conatus Pharmaceuticals Inc :Conatus Pharmaceuticals Inc reports third quarter 2017 financial results and program updates.Q3 revenue $9.6 million.Q3 revenue view $16.1 million -- Thomson Reuters I/B/E/S.Conatus Pharmaceuticals Inc - qtrly ‍net loss per share $0.13.  Full Article

EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - Conatus Pharmaceuticals Inc :EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC.Conatus Pharmaceuticals - ‍continue to evaluate potential internal, external opportunities with goal of announcing initial pipeline expansion plans later in 2017​.  Full Article